Home | Search | Site Map | Contact Us
IoN Home Bar


Nanotechnology: Towards Reducing Animal Testing


(click on title to view abstract of presentation)

Date: 28th May 2008
09.00 - 09.35 Registration
09.40 - 09.50 Welcome and introduction
09.55 - 10.30 Keynote speaker:
Dr Sandra Coecke, IHCP-ECVAM
New technologies Require Different Thinking:
2 Decades of Cell-based Methods for Test Development and Validation for Regulatory Purposes
Session 1: Toxicology and Drug Design
10.35 - 11.00 Dr Béatrice Schaack, CEA Grenoble - DSV/ iRTSV Toxicity Assays in Nanodrops combining Bioassay and Morphometric Endpoints
  • Endpoints in nanotoxicology
  • Cell on chip screening
  • Cell targets in nanotoxicology
11.05 - 11.30 Dr Kelly BéruBé, Cardiff University An In Vitro Human Tissue Equivalent Model of Respiratory Epithelia for Toxicological Screening of Inhaled Nanoparticles
11.35 - 11.55 Refreshments
12.00 - 12.25 Dr J Malcolm Wilkinson,
Kirkstall Ltd
A Novel Multichamber Bioreactor System for Early Stage Toxicology Screening
12.30 - 12.55 Prof Ken Donaldson, University of Edinburgh Towards a structure activity relationship (SAR) for nanoparticles
13.00 - 14.00 Lunch and Networking
Session 2: Tissue Engineering, other novel models and testing strategies
14.05 - 14.30 Dr John Haycock , University of Sheffield A 3D Tissue Engineered Skin Model for Detecting Pro-Inflammatory Responses to Toxic and Cosmetic Agents in Real Time
14.35 - 15.00 Dr Fanqing Frank Chen, Lawrence Berkley National Laboratory Molecular Biomarkers for Bio-nano Interactions
15.05 - 15.30 Dr Anna Price, European Commission JRC

ECVAM Strategy for in vitro Neurotoxicity Testing for regulatory purposes: application of nano- and emerging technologies

  • The present approach used for neurotoxicity testing of chemicals and drugs.
  • Characterization of in vitro models and endpoints suitable for neurotoxicity evaluation.
  • Application of emerging technologies such as multielectrode array measurements of neuronal electrical activity and metabolite profiling as possible endpoints for in vitro neurotoxicity testing.
15.35 - 15.55 Refreshments
16.00 - 16.25 Dr Katy Taylor, BUAV

Alternatives to Animals for Determining the Toxicity of Nanoparticles

  • Risks and benefits of nanotechnology in terms of animal welfare.
  • Update on current European regulatory and public concerns with regard to nanotechnology, animals and alternatives.
  • How alternatives can be used to answer important research and toxicological questions (testing strategies).
16.30 - 16.55 Ulrich Krühne, Teknologisk Institut Towards User Defined Prototyping of µ - bioreactors
17.00   Closing remarks for day 1


Date: 29th May 2008
09.20 - 09.30 Introduction and Welcome to Day 2
Session 3: Imaging and Diagnostics
09.30 - 09.55 Dr Peter Ertl, Austrian Research Centers (ARC) GmbH Assessing Health Effects of Nanoparticles using a Lab-on-a-Chip
10.00 - 10.25 Dr Antonio Garcia, Arizona State University Molecular Diagnosis using a Single Drop of Biological Fluid
10.30 - 10.55 Dr Nirmala Bhogal, FRAME Nanodevices: Where Animal Tests Fail to Meet Testing Needs
11.00 - 11.25 Refreshments

11.30 - 13.00

Panel Discussion -
  • Prof Maurice Whelan, European Commision JRC
  • Michelle Thew, CEO, BUAV
  • 13.00 - 14.10 Lunch
    Session 4: Regulatory and Legal Issues
    14.15 - 14.40 Dr Rosemary Gibson, Centre for Interdisciplinary NanoResearch at Health and Safety Laboratory Testing toxicity of manufactured nanoparticles - How in-vitro methods can fit into an overall regulatory approach
    14.45 - 15.10 Professor Shervanthi Homer-Vanniasinkam, Consultant Vascular Surgeon, Leeds General Infirmary Professor of Translational Vascular Medicine, Leeds Medical School Alternative Preclinical Testing Modalities: a Clinician-Scientist's Perspective
    15.15 - 15.40 Dr Arianna Ferrari, Darmstadt University of Technology The Hyped Nano and the Stressed Laboratory Animal
    15.40 - 16.00 Dr Andy Bennett, FRAME Closing Remarks


    For further information contact Gemma McCulloch, gemma.mcculloch@nano.org.uk

    Feedback | Privacy Policy | Terms of Use | © 2008 Institute of Nanotechnology